<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?</h1>
  <ul>
<li>Moreover, its adjusted EPS of $4.52 surpassed the Street’s estimates by 6.6%.</li>
<li>4, Vertex Pharmaceuticals released its Q2 results, and its shares plummeted 20.6%.</li>
<li>Longer term, VRTX has plunged 1.6% on a YTD basis, lagging behind $SPX’s 10.2% rise.</li>
<li>Shares of REGN have declined 50.2% in the last 52 weeks and 19.5% on a YTD basis.</li>
<li>Driven by continued momentum, the company’s topline for the quarter surged 12.1% year-over-year to $2.96 billion, exceeding the consensus estimates by 2.6%.</li>
<li>More News from Barchart - CPI, S&amp;P 500 Additions and Other Key Things to Watch this Week - Analysts Keep Raising Shopify's Targets - Make a 3.0% Yield in One-Month SHOP OTM Puts However, the biopharmaceutical titan has f</li>
<li>8, 2024.</li>
</ul>
<p><a href="https://finance.yahoo.com/m/59379879-7a6a-342d-9125-5ff3f88c0168/is-vertex-pharmaceuticals.html">Source</a> · 2025-09-08T12:35:30+00:00</p>
</body>
</html>